Validation of a new mass screening tool for cognitive impairment: Cognitive Assessment for Dementia, iPad version
Received 4 January 2013
Accepted for publication 22 February 2013
Published 26 March 2013 Volume 2013:8 Pages 353—360
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Keiichi Onoda,1 Tsuyoshi Hamano,2 Yoko Nabika,1 Atsuo Aoyama,1 Hiroyuki Takayoshi,1 Tomonori Nakagawa,1 Masaki Ishihara,1 Shingo Mitaki,1 Takuya Yamaguchi,1 Hiroaki Oguro,1 Kuninori Shiwaku,3 Shuhei Yamaguchi1
1Department of Neurology, 2Center for Community-Based Health Research and Education, Shimane University, Izumo, 3Shimane University, Matsue, Shimane, Japan
Background: We have developed a new screening test for dementia that runs on an iPad and can be used for mass screening, known as the Cognitive Assessment for Dementia, iPad version (CADi). The CADi consists of items involving immediate recognition memory for three words, semantic memory, categorization of six objects, subtraction, backward repetition of digits, cube rotation, pyramid rotation, trail making A, trail making B, and delayed recognition memory for three words. The present study examined the reliability and validity of the CADi.
Methods: CADi evaluations were conducted for patients with dementia, healthy subjects selected from a brain checkup system, and community-dwelling elderly people participating in health checkups.
Results: CADi scores were lower for dementia patients than for healthy elderly individuals and correlated significantly with Mini-Mental State Examination scores. Cronbach’s alpha values for the CADi were acceptable (over 0.7), and test–retest reliability was confirmed via a significant correlation between scores separated by a one-year interval.
Conclusion: These results suggest that the CADi is a useful tool for mass screening of dementia in Japanese populations.
Keywords: dementia, mass screening, early detection, iPad
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]